- Details
- Alicia Morgans, MD, MPH and Min Yuen Teo, MD, discuss areas of unmet need in bladder cancer treatment, including in the management of patients with non-metastatic muscle-invasive bladder cancer, as well as those who develop metastatic or progressive disease. At Memorial Sloan Kettering, Dr. Teo’s research group has focused on three themes: How to improve the efficacy of cisplatin-based chemotherap...
|
- Details
- In this 2019 LUGPA CME presentation by Neal Shore, he makes the case that now is the time to be developing your advanced bladder cancer clinics. There has been a tremendous amount of advancement in frontline metastatic bladder cancer and Neal Shore highlights some of the rapid changes in the field of both metastatic locally advanced and high-risk bladder cancer. PD receptor blockers, FGFR-targetin...
|
- Details
- In this conversation, Ronac Mamtani and Ravi Parikh join Alicia Morgans to discuss their recent work on bladder cancer outcomes and effectiveness research. They discuss immune checkpoint therapy versus carboplatin chemotherapy in patients with metastatic urothelial cancer (mUC). They also discuss the "Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cance...
|
- Details
- Bishoy Faltas and Charles Ryan discuss some of Bishoy's work using cell-free DNA, or circulating tumor DNA, and what it means in urothelial cancer today. Circulating tumor DNA is DNA that's shed by the tumor into the bloodstream, and the advantage of the current technology and the evolving technology is that we can actually get that DNA. In this work being discussed Bishoy and colleagues are focus...
|
- Details
- Alicia Morgans hosts Bishoy Faltas in a discussion about a Nature Communications publish article Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling which Bishoy was a co-author on with Brian D Robinson et al. In this study an integrated analysis of whole-exome and RNA sequencing of upper tract urothelial carcinoma (UTUC) was performed...
|
- Details
- Professor Matt Galsky joins Alicia Morgans to share details of an analysis looking at FGFR mutations in patients who have received checkpoint inhibitor therapy on clinical trials. In this study, Matt Galsky and colleagues examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring C...
|
- Details
- Alicia Morgans and Petros Grivas discuss the use of antibody-drug conjugates (ADC) as a new approach for the treatment of metastatic urothelial carcinoma (mUC). The two review the latest data presented at the 2019 American Society of Clinical Oncology meeting, specifically the use of enfortumab vedotin. Dr. Grivas further discusses sacituzumab govitecan, another popular ADC, and the promising clin...
|
- Details
- Petros Grivas and Alicia Morgans join in a conversation about the recently FDA accelerated approval of erdafitinib in metastatic bladder cancer for tumors that exhibit mutations active isoforms of FGFR 2 and FGFR 3. Dr. Grivas discusses the companion biomarkers used in the determination of genomic sequencing of the tumor tissue exhibiting FGF reception mutations. The indication for erdafitinib (pa...
|
- Details
- In the rapidly evolving landscape of urothelial cancer, Alicia Morgans and Petros Grivas discuss biomarker testing in patients in urothelial cancer with an emphasis on muscle-invasive and metastatic disease. Having an effect on the day to day treatment algorithms, Petros fields questions in the metastatic setting including who are the patients we are testing and how we are using the results. Biogr...
|
- Details
- Ali Khaki joins Petros Grivas in a discussion on the performance status and response to immune checkpoint inhibition in patients with advanced urothelial cancer. These checkpoint inhibitors have changed the landscape of treatment for urothelial cancer and there has been more and more interest in using them in people who are not suitable for chemotherapy, as approved in the post-platinum setting, a...
|
